About Baxalta
Baxalta is a Healthcare company based in Chicago (United States) founded in 2015, and was acquired by Shire in January 2016. Developer of therapies for orphan diseases and other disease conditions. Its chief executive, as recorded, is Flemming Ornskov. Baxalta offers products and services including Oncology Medicines, Rare Disease Therapies, and Vaccine Products. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is Takeda Pharmaceutical Company Limited. Its competitors include Insitro, BridgeBio and Forge Biologics; 3 of its 3 listed competitors have raised funding.
Company details
Baxalta was founded in 2015 and is headquartered in Chicago, United States. Therapies targeting orphan diseases and underserved conditions are developed, manufactured, and commercialized within the biotechnology sector. Operations center on hematology, oncology, and immunology, with a product pipeline featuring biologics that incorporate novel mechanisms and advanced technology platforms.
- Headquarters Chicago, United States
- Stage Acquired
- SectorsHealthcare
- Website baxalta.com
- Social LinkedIn X
- Acquired by Shire (Jan 2016)
- Legal Name Takeda Pharmaceutical Company Limited
- Investors
- Acquired byShire
(Jan 2016)
Products & Services of Baxalta
Baxalta offers a comprehensive portfolio of products and services, including Oncology Medicines, Rare Disease Therapies, and Vaccine Products.
Treatments for cancer through innovative drug development
Solutions for immunology and metabolic disorders via clinical research
Infectious disease prevention through advanced manufacturing
Investors in Baxalta
Baxalta has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Takeda Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Rare disease treatments are developed by a specialty biopharmaceutical firm. | 1986 | shire.com | Dublin, Ireland |
Investor details for Baxalta
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Baxalta
49 people are tracked at Baxalta (16 in leadership, 1 in board & advisors, 32 in team).
| Name | Role | Group |
|---|---|---|
Flemming Ornskov | CEO | Leadership |
Christophe Weber | President, CEO & Representative Director | Leadership |
Teresa Bitetti | President, Global Oncology Business Unit | Leadership |
Milano Furuta | President, Japan Pharma Business Unit | Leadership |
Mwana Lugogo | Chief Ethics & Compliance Officer | Leadership |
Andrew S. Plump | Director & President, Research & Development | Leadership |
Ramona Sequeira | President, Global Portfolio Division | Leadership |
Koki Sato | Corporate Strategy Officer & Chief of Staff | Leadership |
Chris Lewallyn | Sr Director, Global Compensation | Leadership |
Giles Platford | President, Plasma-Derived Therapies Business Unit | Leadership |
Costa Saroukos | CFO & Director | Leadership |
Takako Ohyabu | Chief Global Corporate Affairs & Sustainability Officer | Leadership |
Gabriele Ricci | Chief Data & Technology Officer | Leadership |
Kevin Harding | Director Engineering | Leadership |
Francisco Samir Serralde | Head Of Sales Mexico | Leadership |
Judith Murphy | Sr. Director, External Partnerships | Leadership |
Jean-Luc Butel | External Director | Board & advisors |
Lauren Duprey | CHRO | Team |
Yoshihiro Nakagawa | Global General Counsel | Team |
Thomas Wozniewski | Global Manufacturing & Supply Officer | Team |
29 more people are available in the full profile.
Complete people profiles for Baxalta
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Baxalta
2 dated milestones of Baxalta across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Baxalta is founded.
- Exit Acquired by Shire.
Competitors of Baxalta
Baxalta has 3 listed competitors in our database, 3 of them funded. They include Insitro, BridgeBio and Forge Biologics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. |
Detailed competitors of Baxalta
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Baxalta
Websites that share an audience with Baxalta (baxalta.com).
Websites whose visitors overlap most with Baxalta. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| google.com | 100% | 85.8B | #1 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Baxalta (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Baxalta
Complete news archive for Baxalta
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Baxalta
Baxalta was founded in 2015.
Baxalta is headquartered in Chicago, United States. It is registered at Chicago, Illinois, United States.
Flemming Ornskov is the CEO of Baxalta, as recorded in our data.
Baxalta was founded in 2015 and is headquartered in Chicago, United States. Therapies targeting orphan diseases and underserved conditions are developed, manufactured, and commercialized within the biotechnology sector. Operations center on hematology, oncology, and immunology, with a product pipeline featuring biologics that incorporate novel mechanisms and advanced technology platforms.
Baxalta's top competitors include BridgeBio, Forge Biologics and Insitro.
Baxalta offers Oncology Medicines, Rare Disease Therapies, and Vaccine Products.
Baxalta has 1 investor. Key investors include Takeda Pharmaceuticals.
Baxalta operates through Takeda Pharmaceutical Company Limited.
Yes. Baxalta was acquired by Shire in January 2016.